|
Q4 2024
|
3 |
74,957 |
NPCE, SGHT, ALRN
|
13F-HR
|
1/15/2025 |
000101297525000044 |
|
Q3 2023
|
3 |
70,387 |
NPCE, SGHT, ALRN
|
13F-HR
|
11/1/2023 |
000101297523000447 |
|
Q2 2023
|
3 |
63,790 |
SGHT, NPCE, ALRN
|
13F-HR
|
7/25/2023 |
000101297523000304 |
|
Q1 2023
|
3 |
67,323 |
SGHT, NPCE, ALRN
|
13F-HR
|
5/5/2023 |
000101297523000207 |
|
Q4 2022
|
3 |
66,746 |
SGHT, NPCE, ALRN
|
13F-HR
|
1/31/2023 |
000101297523000053 |
|
Q3 2022
|
3 |
51,557 |
SGHT, NPCE, AILERON THERAPEUTICS, INC.
|
13F-HR
|
10/31/2022 |
000095012322010592 |
|
Q2 2022
|
4 |
71,172 |
SGHT, NPCE, IMUX, AILERON THERAPEUTICS, INC.
|
13F-HR
|
8/9/2022 |
000095012322008165 |
|
Q1 2022
|
4 |
102,481 |
SGHT, NPCE, IMUX, AILERON THERAPEUTICS, INC.
|
13F-HR
|
5/11/2022 |
000095012322005182 |
|
Q4 2021
|
4 |
141,608 |
SGHT, NPCE, IMUX, AILERON THERAPEUTICS, INC.
|
13F-HR
|
2/11/2022 |
000095012322002186 |